Physician profile
Max Liebo
NPI 1306082094
$2,430.05
in general payments reported to CMS, 2019-2025
16 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $105 · 2021: $245 · 2022: $168 · 2023: $395 · 2024: $248 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118 · Travel and Lodging: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.33 |
| Travel and Lodging | $668.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,620.55 | 2019-2025 | Impella |
| Abbott Laboratories | $375.28 | 2019-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Akcea Therapeutics, INC. | $133.00 | 2020-2021 | |
| Cvrx, INC. | $73.85 | 2021-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $67.87 | 2020-2025 | |
| Livanova USA, INC. | $31.28 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $31.24 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.51 | 2024 | Jardiance |
| Pfizer INC. | $21.00 | 2024 | |
| Bridgebio Pharma, INC. | $19.88 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $19.28 | 2024 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $14.31 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Liebo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.